Losartan: Nursing Drug Guide, Hyperkalemia & Hold Rules
Cozaar blocks angiotensin II at the AT1 receptor to lower blood pressure and slow diabetic nephropathy progression, but nurses must watch for hyperkalemia, renal function decline, and symptomatic hypotension when diuretics or NSAIDs overlap—and discontinue immediately when pregnancy is detected because RAS drugs can injure the fetus.
The Cozaar boxed warning states that when pregnancy is detected, losartan should be discontinued as soon as possible because drugs acting on the renin–angiotensin system can injure or cause death of the developing fetus. Labeling also warns about symptomatic hypotension in volume- or salt-depleted patients (often on diuretics), renal function deterioration, and hyperkalemia—especially with potassium-raising drugs or dual RAS blockade. Angioedema has been reported rarely with losartan, including in patients with prior ACE inhibitor angioedema; discontinue and escalate airway care when breathing is threatened.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every losartan dose, reconcile pregnancy status, airway-threatening swelling, and whether a new diuretic or NSAID could trigger symptomatic hypotension or a creatinine/potassium jump—Cozaar labeling emphasizes supervised first doses when diuretics cannot be stopped.
Most common brand names
Losartan potassium is an angiotensin II receptor blocker (ARB). The reference U.S. brand is Cozaar (25 mg, 50 mg, and 100 mg tablets). Fixed combinations with hydrochlorothiazide are common on formularies—confirm both ingredients on every order. Pharmacy may compound an oral suspension from tablets per manufacturer directions for patients who cannot swallow solids. Trace every product through medication reconciliation rather than relying on look-alike labels.
Why we give it — Indications
Cozaar prescribing information approves losartan for hypertension in adults and pediatric patients ≥6 years, to reduce stroke risk in hypertensive patients with left ventricular hypertrophy (often in patients with heart failure risk factors), and for diabetic nephropathy with elevated serum creatinine and proteinuria (urinary albumin-to-creatinine ratio ≥300 mg/g) in type 2 diabetes with hypertension history. Nurses on medical–surgical units most often give the daily oral dose; nephrology and primary-care teams titrate for renal protection per diabetic nephropathy pathways.
| Use | Detail |
|---|---|
| Hypertension | Lowers blood pressure in adults and children ≥6 years; usual adult start 50 mg once daily (max 100 mg/day). |
| Stroke risk (LVH) | Reduces stroke risk in hypertensive adults with left ventricular hypertrophy; may add HCTZ or increase losartan to 100 mg if further BP response needed. |
| Diabetic nephropathy | Slows nephropathy progression (doubling of serum creatinine or ESRD) in type 2 diabetes with proteinuria and hypertension history. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Losartan selectively blocks the AT1 angiotensin II receptor, reducing vasoconstriction and aldosterone-mediated sodium retention without inhibiting ACE directly. An active carboxylic acid metabolite contributes substantially to antihypertensive effect. Because ARBs do not block bradykinin breakdown, patients switching from an ACE inhibitor often report less dry cough—though rare angioedema still occurs. Reduced aldosterone activity can raise serum potassium and blunt compensatory renal perfusion in volume-depleted states—core reasons for electrolyte and blood pressure surveillance on shift.
Dosing overview
Doses below reflect the reviewed Cozaar label; titrate to prescriber orders, blood pressure response, and renal-electrolyte trends. Track eGFR with serum creatinine on the basic metabolic panel.
Missed dose: Not specified in the reviewed prescribing information for a universal rule—follow prescriber guidance and institutional protocol; do not double doses.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption / onset | Well absorbed; antihypertensive effect often within 1 week of starting therapy (maximal effect in some studies 3–6 weeks) | Still monitor for hypotension when volume-depleted even though peak BP effect is not immediate |
| Active metabolite | Carboxylic acid metabolite contributes substantially to effect; hepatic impairment raises losartan and metabolite exposure | Use 25 mg start in mild-to-moderate hepatic impairment per label |
| Elimination | Renal excretion predominates; elevated plasma concentrations in renal insufficiency; neither parent drug nor active metabolite removed by hemodialysis (overdosage) | Renal impairment needs potassium/creatinine surveillance; overdose support is not dialysis-dependent |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm pregnancy status or reliable contraception in patients of reproductive potential—discontinue immediately if pregnancy is detected or suspected
- Review baseline and trended serum creatinine, eGFR, and potassium—especially with diabetes, dehydration, or concurrent nephrotoxic drugs
- Assess volume status and recent diuretic changes; symptomatic hypotension risk rises when salt or volume depletion is present
- Screen medication lists for NSAIDs, potassium supplements, potassium-sparing diuretics (e.g. spironolactone), other RAS agents (lisinopril, enalapril), and aliskiren combinations
Contraindications (FDA label summary)
- Hypersensitivity to any component of losartan potassium tablets
- Coadministration with aliskiren in patients with diabetes
Important interactions
| Drug / scenario | Effect | Nursing action |
|---|---|---|
| Loop diuretics, thiazide diuretics | Symptomatic hypotension when volume- or salt-depleted; correct depletion before losartan per label | Take orthostatic vitals closely first two weeks and after dose tweaks; escalate symptomatic hypotension or oliguria |
| Potassium-retaining therapies | Agents raising serum potassium may cause hyperkalemia—monitor potassium per label | Ensure scheduled laboratory follow-up potassium review; withhold scheduled dose when clinically ordered for critical lab abnormalities pending prescriber contact |
| NSAID / COX-2 inhibitors | Reduced antihypertensive effect plus worsened renal impairment risk | Educate OTC avoidance without prescriber review; monitor creatinine and blood pressure pairing when unavoidable short courses emerge |
| Dual RAS inhibition | Higher renal dysfunction hypotension potassium disturbances | Increased risk of hypotension, syncope, hyperkalemia, and renal impairment—avoid routine dual RAS blockade; VA NEPHRON-D trial cited in label |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet or pharmacy-compounded suspension (per manufacturer directions in labeling).
- Cozaar tablets: 25 mg, 50 mg (scored), and 100 mg; swallow intact unless pharmacy directs otherwise
- May be taken with or without food; maintain a consistent daily schedule for blood pressure trending
- Suspension prepared from tablets must be refrigerated 2–8 °C, shaken before each dose, and used within compounding stability window per label—administer only pharmacy-prepared suspension
- Do not confuse losartan with look-alike antihypertensives (see LASA section)
Expected therapeutic response
- Antihypertensive effect is often present within about 1 week; in some studies maximal effect occurred at 3–6 weeks
- In diabetic nephropathy, slowing of creatinine doubling or progression to dialysis/transplant is the long-term renal outcome studied in labeling
- Patients should report improved blood pressure readings at home or clinic once volume status is stable and hypotension symptoms absent
Red flags — Stop and act
Escalate immediately when these cues appear during losartan therapy:
- Pregnancy detected or reliably suspected—hold losartan and notify prescriber for urgent obstetric/medication review
- Lip, tongue, or facial swelling with voice change or inspiratory difficulty—rare losartan angioedema can obstruct the airway
- Symptomatic hypotension, syncope, or collapse—especially after diuretic intensification or dehydration
- Rapidly rising potassium or creatinine, oliguria, or nausea with renal trajectory suggesting acute kidney injury
- Signs of hyperkalemia (weakness, palpitations, ECG changes per protocol) when potassium-sparing drugs or supplements overlap
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Dizziness, URI, nasal congestion, back pain | Hypertension trials (≥2% and more common than placebo): dizziness 3%, upper respiratory infection 8%, nasal congestion 2%, back pain 2% | Teach orthostatic caution; distinguish nuisance symptoms from hypotension or angioedema |
| Hypotension, hyperkalemia, renal effects | RENAAL and other trials: hypotension, orthostatic hypotension, hyperkalemia, diarrhea, anemia reported with ≥2% difference vs placebo background therapy | Monitor BP, potassium, creatinine; hold and notify when clinically significant deterioration |
| Angioedema, rash, vasculitis (postmarketing) | Rare angioedema (face, lips, tongue, larynx); rash; vasculitis including Henoch-Schönlein purpura; anaphylactic reactions reported | Discontinue at first airway-threatening swelling; escalate allergy/renal evaluation for vasculitis cues |
On a small screen, swipe or scroll sideways to see the full table.
Overdose management
Human losartan overdosage data are limited in labeling. Animal lethality occurred at very high oral doses. The most likely human manifestation is hypotension; there is no specific reversal agent cited.
Recommended supportive therapies (label)
- Intravenous normal saline infusion for hypotension
- Losartanat may be removed by hemodialysis; peritoneal dialysis removed losartan from neonatal circulation in labeling examples
- Supportive perfusion, airway, and electrolyte monitoring per institutional toxicology protocol
- Consult local poison control / toxicology services per facility protocol when ingestion amount or intent is uncertain
Consult local poisoning or toxicology services per institutional policy when intentional overdose ingestion volume remains uncertain—even though labeling describes no reversal agent analogous to opioids or acetaminophen pathways.
Look-alike / sound-alike and error prevention
- Losartan versus lisinopril / enalapril / valsartan: ARB and ACE inhibitor names sound similar—barcode every dose and read both brand and generic on the label
- Losartan versus losartan–HCTZ combination tablets: verify monotherapy versus fixed pairs to avoid duplicate antihypertensive classes
- Strength selection: 25 mg, 50 mg, and 100 mg tablets (codes 951, 952, 960 per label) sit near each other in ADCs—witness high-strength pulls
- “Potassium” confusion: losartan potassium salt is not potassium chloride replacement—never administer as electrolyte repletion
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Swallow intact | Standard Cozaar tablets are intended orally intact; compounded suspension exists only via pharmacy-specific preparation—not ad hoc crushed tablets unless pharmacy validates stability. |
| Meal pairing | Eating shifts active metabolite peak latency without prohibiting coexistence consistent meals—steady daily pattern assists timing vitals trending. |
| Orthostatics | Volume-depleted hospitalized patients merit lying-standing blood pressure coupling during initial therapy weeks aligning warning language. |
| Airway adjunct readiness | Because angioedema may involve laryngeal structures rapidly, bedside teams benefit confirming emergency airway equipment availability zones when initiating new RAS inhibitor courses high-risk phenotype. |
| Pharmacy escalation triggers | Uncertainty about breastfeeding safety neprilysin transition windows lithium co-therapy dosing or suspension compounding should route through pharmacist corroboration before administration finishes. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pregnancy | Discontinue as soon as pregnancy is detected. Second- and third-trimester RAS exposure can reduce fetal renal function, cause oligohydramnios-related lung hypoplasia and skeletal deformations, and neonatal hypotension, anuria, or renal failure per label. |
| Chronic kidney disease / renovascular risk | Renal artery stenosis, severe heart failure, or volume depletion may predispose to acute renal failure on losartan—monitor renal function periodically and consider withholding or discontinuing when clinically significant decline occurs. |
| Pediatrics | Established ages 6–16 years for hypertension; not recommended <6 years or GFR <30 mL/min/1.73 m². Usual start 0.7 mg/kg once daily (up to 50 mg). |
| Black ancestry monotherapy caveat | LIFE study subgroup: Black patients with LVH on atenolol (+HCTZ background) had different composite CV outcomes than those on losartan—interpretation limited; ensure individualized prescribing and monitoring per clinician—not a nursing hold criterion alone. |
| Lactation | LactMed cites low breastmilk concentrations with modeled infant ingestion under 0.14% maternal weight-adjusted doses predominantly active metabolite whose oral bioavailability clinically trivial—overall infant risk expectation low individualized discussion remains standard. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure, heart rate, and hydration status after initiation, dose increases, and restarts following intercurrent illness—complete orthostatic blood pressure sets when diuretics overlap; labeling warns about symptomatic hypotension with volume depletion
- Serum creatinine and eGFR trends with electrolytes on the basic metabolic panel, including potassium
- Orthostatic blood pressure when diuretics overlap or after illness-related dehydration
- Signs of angioedema or anaphylaxis—especially in patients with prior ACE inhibitor angioedema
Document
- Dose, route, time, indication, blood pressure, orthostatic symptoms, OTC NSAID use, and potassium supplements or salt substitutes
- Patient education on pregnancy avoidance, angioedema warning signs, dehydration risk, and OTC NSAID/potassium supplement use
- Prescriber/pharmacist notifications, hold decisions, rapid response or airway interventions, and repeat lab trends
Patient teaching
- Report possible pregnancy immediately—losartan must be stopped as soon as pregnancy is detected per boxed warning
- Facial, lip, tongue, or throat swelling, hoarseness, or trouble breathing means stop the drug and seek emergency care—do not take another dose
- Do not start potassium supplements, salt substitutes, or potassium-sparing diuretics without prescriber approval
- Report dizziness, fainting, vomiting, diarrhea, or reduced fluid intake—volume loss raises hypotension risk with ARBs
- Check with the care team before OTC NSAIDs (e.g. ibuprofen)—combined use can worsen kidneys and blunt blood pressure control
- Take losartan at the same time each day; do not double doses if one is missed—follow prescriber or pharmacist instructions
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Pregnancy confirmed or suspected—discontinue immediately and notify prescriber for obstetric follow-up
- Angioedema or airway-threatening swelling of face, lips, tongue, or throat—hold and escalate per emergency protocol
- Hyperkalemia per institutional critical value, symptomatic hypotension, syncope, or shock until volume status reviewed
- Oliguria or clinically significant creatinine rise after dehydration, NSAID use, or dual RAS-blocking therapy
- Order conflicts: losartan with aliskiren in diabetes, or prohibited dual RAS blockade per facility policy—clarify before administering
Clinical practice integration and workflow
1. Stewardship checkpoints
- Barcode-verify losartan strength (25 / 50 / 100 mg) and combination product name before every pass
- Pair blood pressure captures with electrolyte renal panels after therapy starts or adjunct drugs change
- Screen admission medication lists for OTC renal stressors undocumented preadmission NSAID aspirin stacks
2. High-alert designation
Not universally classified institutional high-alertTreat losartan with proportional vigilance analogous high-stakes cardiometabolic meds because fetal catastrophe airway angioedema and renal failure potentials exceed ordinary oral antihypertensive error tolerance.
3. Hold and question cues
- New lip or tongue swelling or voice change—hold losartan and treat as airway emergency until cleared
- Creatinine jump ≥30% clinician-defined institution thresholds after RAS initiation mandates hold clarification per policy
- Patient purchased OTC anti-inflammatory pills without informing team—coordinate pause teaching prescriber review
Teach-back prompts
- “Which swelling symptoms mean you skip further doses tonight?” (Patient should articulate face lip tongue airway difficulty emergency activation.)
- “Why should potassium salt substitutes worry your heart team?” (Patient links ARB therapy to hyperkalemia risk.)
Pharmacist: Dual RAS therapy review, potassium binder coordination, NSAID courses, suspension compounding, breastfeeding risk–benefit, aliskiren interaction checks.
Prescriber / nephrology: Diabetic nephropathy titration, resistant hypertension, pregnancy planning, hyperkalemia management, renal artery stenosis suspicion, angioedema recurrence after ACE inhibitor.
🧠 Quick mental checklist
- Pregnancy ruled out or already escalated if suspected?
- Potassium and creatinine trends acceptable for today’s dose?
- Volume status fair after diuretics, vomiting, or poor intake?
- Any lip, tongue, or throat swelling since last dose?
- NSAIDs, potassium supplements, or duplicate RAS drugs on the MAR?
Losartan NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for losartan: use the case tabs (MAR, Labs, History, Nursing notes) for priority actions, SATA cue recognition, potassium/creatinine trend SATA, urgency matrix sorting, pregnancy teaching MCQ, and overdose cloze—focused on hyperkalemia, fetal toxicity, and hypotension without a labeled antidote.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Cozaar (losartan potassium) 50 mg PO daily at 0900—due now (day 3 of therapy)
- Hydrochlorothiazide 25 mg PO daily at 0800
- Potassium chloride 20 mEq PO daily—started yesterday per new order
- Metformin 1000 mg PO twice daily with meals
- Potassium: 4.4 → 4.9 → 5.8 mEq/L (repeat pending)
- Serum creatinine: 1.1 → 1.3 → 1.7 mg/dL
- eGFR ~48 mL/min/1.73 m² (calculated in EHR)
- Urinalysis: proteinuria noted on admission (diabetic nephropathy history)
- Type 2 diabetes, hypertension, diabetic nephropathy on losartan for renal protection
- Home BP logs averaging 138/84 mm Hg before admission
- Denies pregnancy; LMP 3 weeks ago per chart; not trying to conceive
- Prior lisinopril stopped 6 months ago for dry cough—no documented angioedema
- Patient reports new muscle weakness and palpitations since breakfast; ECG not yet done
- BP sitting 118/72 mm Hg, HR 88—no orthostatic set completed this shift
- Night nurse documented patient took extra potassium supplement from home bag—removed and pharmacy notified
Answer key & rationale
Frequently asked questions
Why is hyperkalemia the top electrolyte concern with losartan?
Angiotensin II receptor blockade reduces aldosterone-driven potassium excretion. Cozaar labeling directs periodic serum potassium monitoring and dose reduction or discontinuation when hyperkalemia develops, especially with potassium supplements, potassium-sparing diuretics, or other drugs that raise potassium.
What should nurses do if pregnancy is detected on losartan?
Discontinue losartan as soon as possible. The boxed warning states drugs acting on the renin-angiotensin system during the second and third trimesters can reduce fetal renal function and cause fetal and neonatal morbidity and death, including oligohydramnios-related complications and neonatal renal failure.
Can losartan cause angioedema like ACE inhibitors?
Yes, although less common than with ACE inhibitors. Cozaar postmarketing data report rare angioedema involving the face, lips, tongue, or larynx—including airway obstruction—and some patients had prior ACE inhibitor angioedema. Discontinue immediately and escalate airway care when breathing is threatened.
Is there an antidote for losartan overdose?
Limited human overdosage data exist. Labeling states the most likely manifestation is hypotension and tachycardia, with possible bradycardia from vagal stimulation; treat with supportive care. Neither losartan nor its active metabolite can be removed by hemodialysis per prescribing information.
Can patients breastfeed while taking losartan?
It is not known whether losartan is excreted in human milk; significant levels were present in rat milk. Cozaar labeling advises choosing either breastfeeding or losartan—not both—after weighing drug importance to the mother. Use LactMed and prescriber guidance for individualized counselling.
Why start 25 mg instead of 50 mg for some adults?
A 25 mg starting dose is recommended for adults with possible intravascular volume depletion—for example those on diuretic therapy—because symptomatic hypotension may occur after ARB initiation until volume status is corrected.
References
-
U.S. National Library of Medicine. Cozaar (losartan potassium) tablet — prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39
-
Drugs and Lactation Database (LactMed). Losartan. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM726/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and pharmacist review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.